{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T00:23:07Z","timestamp":1771460587959,"version":"3.50.1"},"reference-count":28,"publisher":"Public Library of Science (PLoS)","issue":"2","license":[{"start":{"date-parts":[[2017,2,7]],"date-time":"2017-02-07T00:00:00Z","timestamp":1486425600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0170750","type":"journal-article","created":{"date-parts":[[2017,2,7]],"date-time":"2017-02-07T13:34:09Z","timestamp":1486474449000},"page":"e0170750","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":8,"title":["Treatment algorithm based on the multivariate survival analyses in patients with advanced hepatocellular carcinoma treated with trans-arterial chemoembolization"],"prefix":"10.1371","volume":"12","author":[{"given":"Hasmukh J.","family":"Prajapati","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3077-9989","authenticated-orcid":false,"given":"Hyun S.","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2017,2,7]]},"reference":[{"issue":"5","key":"ref1","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.1053\/j.gastro.2004.09.011","article-title":"Primary liver cancer: worldwide incidence and trends","volume":"127","author":"FX Bosch","year":"2004","journal-title":"Gastroenterology"},{"issue":"2","key":"ref2","doi-asserted-by":"crossref","first-page":"74","DOI":"10.3322\/canjclin.55.2.74","article-title":"Global cancer statistics, 2002","volume":"55","author":"DM Parkin","year":"2005","journal-title":"CA Cancer J Clin"},{"issue":"2","key":"ref3","doi-asserted-by":"crossref","first-page":"131","DOI":"10.2174\/1568009053202063","article-title":"Treatment modalities for hepatocellular carcinoma","volume":"5","author":"H Hung","year":"2005","journal-title":"Curr Cancer Drug Targets"},{"issue":"5","key":"ref4","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1002\/hep.20933","article-title":"Management of hepatocellular carcinoma","volume":"42","author":"J Bruix","year":"2005","journal-title":"Hepatology"},{"issue":"3","key":"ref5","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/S0168-8278(01)00130-1","article-title":"Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver","volume":"35","author":"J Bruix","year":"2001","journal-title":"J Hepatol"},{"issue":"9399","key":"ref6","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1016\/S0140-6736(03)14964-1","article-title":"Hepatocellular carcinoma","volume":"362","author":"JM Llovet","year":"2003","journal-title":"Lancet"},{"key":"ref7","first-page":"1","article-title":"Safety and Effectiveness of Chemoembolization with Drug-Eluting Beads for Advanced-Stage Hepatocellular Carcinoma","author":"SP Kalva","year":"2013","journal-title":"Cardiovascular and interventional radiology"},{"issue":"3","key":"ref8","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.jvir.2012.11.026","article-title":"Safety and efficacy of doxorubicin drug-eluting bead transarterial chemoembolization in patients with advanced hepatocellular carcinoma","volume":"24","author":"HJ Prajapati","year":"2013","journal-title":"Journal of vascular and interventional radiology: JVIR"},{"issue":"6","key":"ref9","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1016\/j.jhep.2012.01.006","article-title":"Phase II study of concurrent transarterial chemoembolization and sorafenib in patients with unresectable hepatocellular carcinoma","volume":"56","author":"JW Park","year":"2012","journal-title":"J Hepatol"},{"issue":"30","key":"ref10","doi-asserted-by":"crossref","first-page":"3960","DOI":"10.1200\/JCO.2011.37.1021","article-title":"Phase II trial of sorafenib combined with concurrent transarterial chemoembolization with drug-eluting beads for hepatocellular carcinoma","volume":"29","author":"TM Pawlik","year":"2011","journal-title":"Journal of clinical oncology: official journal of the American Society of Clinical Oncology"},{"issue":"7","key":"ref11","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1053\/j.gastro.2014.02.032","article-title":"Development of Hong Kong Liver Cancer staging system with treatment stratification for patients with hepatocellular carcinoma","volume":"146","author":"T Yau","year":"2014","journal-title":"Gastroenterology"},{"issue":"4","key":"ref12","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1093\/annonc\/mds605","article-title":"mRECIST and EASL responses at early time point by contrast-enhanced dynamic MRI predict survival in patients with unresectable hepatocellular carcinoma (HCC) treated by doxorubicin drug-eluting beads transarterial chemoembolization (DEB TACE)","volume":"24","author":"HJ Prajapati","year":"2013","journal-title":"Annals of oncology: official journal of the European Society for Medical Oncology \/ ESMO"},{"issue":"89","key":"ref13","first-page":"213","article-title":"Risk factors for death in 224 cases of hepatocellular carcinoma after transcatheter arterial chemoembolization","volume":"56","author":"A Hiraoka","year":"2009","journal-title":"Hepatogastroenterology"},{"issue":"7","key":"ref14","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1016\/j.jvir.2011.03.005","article-title":"Chemoembolization for hepatocellular carcinoma: multivariate analysis of predicting factors for tumor response and survival in a 362-patient cohort","volume":"22","author":"HT Hu","year":"2011","journal-title":"Journal of vascular and interventional radiology: JVIR"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1186\/1471-230X-10-146","article-title":"Prognostic prediction across a gradient of total tumor volume in patients with hepatocellular carcinoma undergoing locoregional therapy","volume":"10","author":"TI Huo","year":"2010","journal-title":"BMC Gastroenterol"},{"issue":"4","key":"ref16","doi-asserted-by":"crossref","first-page":"919","DOI":"10.2214\/AJR.10.4770","article-title":"Chemoembolization endpoints: effect on survival among patients with hepatocellular carcinoma","volume":"196","author":"B Jin","year":"2011","journal-title":"AJR Am J Roentgenol"},{"issue":"12","key":"ref17","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1016\/j.jvir.2011.08.013","article-title":"Comparative analysis of the safety and efficacy of transcatheter arterial chemoembolization and yttrium-90 radioembolization in patients with unresectable hepatocellular carcinoma","volume":"22","author":"C Lance","year":"2011","journal-title":"Journal of vascular and interventional radiology: JVIR"},{"issue":"7","key":"ref18","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/j.dld.2009.09.012","article-title":"Transcatheter arterial chemoembolisation for hepatocellular carcinoma in cirrhosis: survival rate and prognostic factors","volume":"42","author":"M Olivo","year":"2010","journal-title":"Dig Liver Dis"},{"issue":"3","key":"ref19","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1258\/ar.2010.100369","article-title":"Outcome and prognostic factors of spontaneous ruptured hepatocellular carcinoma treated with transarterial embolization","volume":"52","author":"BS Shin","year":"2011","journal-title":"Acta Radiol"},{"issue":"1","key":"ref20","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/S0720-048X(03)00219-5","article-title":"Transcatheter hepatic arterial chemoembolization for hepatocellular carcinoma invading the portal veins: therapeutic effects and prognostic factors","volume":"51","author":"J Uraki","year":"2004","journal-title":"Eur J Radiol"},{"issue":"5","key":"ref21","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1016\/j.jvir.2012.12.003","article-title":"Multivariate analysis of prognostic factors for survival following doxorubicin-eluting bead transarterial chemoembolization for hepatocellular carcinoma","volume":"24","author":"MT Sellers","year":"2013","journal-title":"Journal of vascular and interventional radiology: JVIR"},{"issue":"5","key":"ref22","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1007\/s00270-012-0394-0","article-title":"Chemoembolization with doxorubicin-eluting beads for unresectable hepatocellular carcinoma: five-year survival analysis","volume":"35","author":"K Malagari","year":"2012","journal-title":"Cardiovascular and interventional radiology"},{"issue":"3","key":"ref23","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1148\/radiol.10091473","article-title":"Chemoembolization for Hepatocellular Carcinoma: Comprehensive Imaging and Survival Analysis in a 172-Patient Cohort1","volume":"255","author":"RJ Lewandowski","year":"2010","journal-title":"Radiology"},{"issue":"2","key":"ref24","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.jvir.2012.10.021","article-title":"Factors affecting survival following chemoembolization with doxorubicin-eluting microspheres for inoperable hepatocellular carcinoma","volume":"24","author":"SP Kalva","year":"2013","journal-title":"Journal of vascular and interventional radiology: JVIR"},{"issue":"3","key":"ref25","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1111\/j.1477-2574.2009.00138.x","article-title":"Prognostic factors for survival in patients with unresectable hepatocellular carcinoma undergoing chemoembolization with doxorubicin drug-eluting beads: a preliminary study","volume":"12","author":"R Dhanasekaran","year":"2010","journal-title":"HPB (Oxford)"},{"issue":"11","key":"ref26","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1097\/01.RVI.0000128123.04554.C1","article-title":"Comparison of MELD and Child-Pugh scores to predict survival after chemoembolization for hepatocellular carcinoma","volume":"15","author":"DB Brown","year":"2004","journal-title":"Journal of vascular and interventional radiology"},{"issue":"1","key":"ref27","doi-asserted-by":"crossref","first-page":"W7","DOI":"10.2214\/AJR.07.3947","article-title":"Hepatocellular carcinoma variants: radiologic-pathologic correlation","volume":"193","author":"YE Chung","year":"2009","journal-title":"American Journal of Roentgenology"},{"issue":"2","key":"ref28","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1148\/radiol.12111550","article-title":"Advanced-stage hepatocellular carcinoma: transarterial chemoembolization versus sorafenib","volume":"263","author":"M. Pinter","year":"2012","journal-title":"Radiology"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0170750","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,10,23]],"date-time":"2018-10-23T23:53:07Z","timestamp":1540338787000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0170750"}},"subtitle":[],"editor":[{"given":"Chien-Wei","family":"Su","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2017,2,7]]},"references-count":28,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2017,2,7]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0170750","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,2,7]]}}}